IRCT20200105046010N24尚未招募未知
In- Vivo Bioequivalence study of Everolimus tablet 10mg ABIDI (NEORAPA® 10mg) with brand drug (AFINITOR® 10mg Novartis) in Iranian healthy volunteers.
ABIDI Pharmaceutical Company0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 60 years（—）
- 性别
- All
入选标准
- •General health
- •Body mass index(18-28)
- •Informed consent
- •Age(18-60)
排除标准
- •A history of cardiovascular disease
- •A history of liver & kidney disease
- •Alcohol & Drug addiction
- •Hypersensitivity to the drug
研究者
相似试验
招募中
不适用
In-vivo Bioequivalence Test of Everolimus tablet with brand drugs (AFINITOR® 10mg Novartis).IRCT20200105046010N44SOBHAN ONCOLOGY Pharmaceutical CO.24
招募中
不适用
In-vivo Bioequivalence Test of Everolimus tablet (ROLIMA® 0.75 mg) with brand drugs (CERTICAN® 0.75 mg, Novartis,Switzerlan).IRCT20200105046010N58anoalvand Pharmaceutical Co.24
招募中
不适用
Bioequivalence study of Everolimus 0.75mg tabletIRCT20200623047902N12Alborz Zagros company24
招募中
不适用
In-vivo Bioequivalence Test of Erlotinib tablets with brand drug (TARCEVA® 150 mg, Rosche, Switzerland)IRCT20200105046010N46Actero Pharma. Co.24
招募中
不适用
In-vivo Bioequivalence Test of Erlotinib tablets with brand drug (TARCEVA® 150 mg, Rosche, Switzerland)Bio equivalence test.IRCT20200105046010N51Abidi Pharmaceutical Company24